Table 1 Factors associated with first-line ARV prices
From: Factors influencing global antiretroviral procurement prices
Antiretroviral drugs+ | EFV 600 mg | 3TC150 mg/ZDV 300 mg | 3TC 150 mg | NVP 200 mg | d4T 40 mg | ZDC 300 mg |
|---|---|---|---|---|---|---|
HIV prevalence 2-5% | -0.079 (-0.247, 0.089) | 0.056 (-0.123, 0.236) | 0.081 (-0.166, 0.328) | 0.126 (-0.003, 0.256) | 0.156 (-0.346, 0.035) | -0.014 (-0.179, 0.152) |
HIV prevalence >5% | -0.120 (-0.301, 0.061) | 0.140 (-0.026, 0.307) | 0.143 (-0.211, 0.497) | 0.100* (0.006, 0.194) | 0.230 (-0.686, 0.226) | -0.008 (-0.056, 0.041) |
Lower-middle income | 0.035 (-0.088, 0.158) | 0.114 (-0.088, 0.316) | 0.053 (-0.242, 0.348) | 0.200 (-0.208, 0.609) | 0.356 (-0.277, 0.989) | 0.027 (-0.212, 0.266) |
Upper-middle income | 0.027 (-0.180, 0.233) | 0.356** (0.295, 0.416) | 0.308* (0.160, 0.456) | 0.390** (-0.295, 0.485) | 0.483* (0.146, 0.820) | 0.190* (0.018, 0.363) |
Volume 2 nd tercile | -0.039 (-0.264, 0.186) | -0.040 (-0.144, 0.063) | -0.041 (0.217, 0.134) | -0.149* (-0.296, -0.002) | 0.120 (-0.280, 0.039) | -0.033 (-0.152 -0.085) |
Volume 3 th tercile | -0.136 (-0.407, 0.135) | -0.034 (-0.196, 0.128) | -0.045 (-0.271, 0.181) | -0.271* (-0.523, -0.020) | -0.143 (0.400, 0.113) | -0.073 (-0.226, 0.079) |
API*** | -0.002 (-0.015, 0.012) | -0.007* (-0.015, 0.000) | -0.013** (-0.019, -0.006) | -0.003 (-0.007, 0.001) | -0.001 (-0.013, 0.011) | 0.001 (-0.011, 0.013) |
Innovator | 0.568** (0.299, 0.837) | 0.736** (0.409, 1.063) | 0.452* (-0.094, 0.810) | 1.730** (1.366, 2.093) | 1.000* (0.372, 1.629) | 0.458** (0.210, 0.705) |
CHAI++ | -0.104 (-0.538, 0.331) | -0.156 (-0.356, 0.042) | -0.264* (-0.511, -0.017) | -0.105 (-0.368, 0.159) | -0.190 (-0.761, 0.382) | 0.015 (-0.335, 0.365) |
PEPFAR+++ | 0.007 (-0.228, 0.242) | -0.089* (-0.194, -0.015) | -0.132 (-0.491, 0.228) | -0.048 (-0.374, 0.278) | 0.015 (-0.325, 0.354) | -0.069 (-0.227, 0.089) |
R-square | 0.338 | 0.390 | 0.305 | 0.560 | 0.396 | 0.183 |
Observations | 1514 | 1519 | 1244 | 1638 | 619 | 771 |